Preclinical Research & Case Studies

Mechanism: A synthetic analog of growth-hormone-releasing hormone (GHRH). The ‘no-DAC’ form (Modified GRF 1-29) resists DPP-IV degradation with a short, pulse-like profile; it binds the GHRH receptor on pituitary somatotrophs, raising cAMP and priming GH synthesis.

• GHRH + GHRP synergy study (1999): Demonstrated that simultaneous stimulation of the GHRH-receptor and ghrelin-receptor pathways produces a synergistic GH response greater than the sum of the individual responses — the mechanistic basis for pairing a GHRH analog with a secretagogue.
  Model: Somatotroph / GH-axis research | Source →
• Teichman et al. (2006), J. Clinical Endocrinology & Metabolism: Pharmacokinetic characterization of the DAC-modified analog reported an extended half-life of roughly 5.8–8.1 days via albumin binding; the no-DAC form, by contrast, is characterized by a ~30-minute half-life that mimics natural pulsatility.
  Model: Pharmacokinetic study (human PK reference) | Source →

Research stage: Published characterization centers on GHRH-analog pharmacology and pharmacokinetics; combination-protocol efficacy data are limited.